Manipal Hospital ties up with Stempeutics

Manipal Super Speciality Hospital (MSSH), has recently tied up with Stempeutics Research, to promote stem cell therapy in Andhra Pradesh. The global market for stem cell therapies is expected to be $20 billion by 2010 and is expected to grow rapidly. Stem cell based products have already been released in the US.
In India, the expected market for stem cell therapy is approximately $540 million. Initially, MSSH will conduct pilot studies for parkinson’s diseases, spinal cord injury, critical limb ischemia and dilated cardio myopathy. Later on, more diseases will be added based on hospital requirements.
T Ramoji, Vice President, Manipal Health Systems, said, “Keeping in mind the overall disease burden of various medical conditions and the potential for stem cell therapy globally, MSSH has taken this new initiative of bringing stem cell therapy to Andhra Pradesh in collaboration with Stempeutics.”
Dr. Prabhakara Rao, Medical Director, MSSH, added, “We are happy about Stempeutics’ commitment in developing Andhra Pradesh as one of the stem cell research and therapy hubs. Our aim is to provide hope to patients suffering from life threatening diseases for which there is no cure. I have seen the world-class facility Stempeutics has created in Bangalore for stem cell isolation and up scaling and the world-class research on adult stem cells and human embryonic stem cells. I am convinced that this collaboration with Stempeutics will go a long way.”